TAMPA, Fla.--(BUSINESS WIRE)--March 30, 2006--Accentia Biopharmaceuticals Inc.'s (NASDAQ:ABPI) manufacturing partner received approval from the U.S. Food and Drug Administration (FDA) for a new dosage of Xodol(R) (hydrocodone bitartrate and acetaminophen tablets, USP), the Company’s unique dosage of this combination pain product. This new dosage affords physicians additional choices in the dose of hydrocodone for patients without exceeding the maximum daily dose of acetaminophen. TEAMM Pharmaceuticals Inc., Accentia’s wholly owned specialty pharmaceutical subsidiary, holds the exclusive U.S. license for the marketing and sale of this product.
